viewAnteris Technologies Ltd

Admedus discharges first patient following clinical SAVR trial

Fifteen patients have been enrolled in the study and will be followed up for 6 months after receiving implantation of the ADAPT single-piece 3D aortic valve.

Admedus Ltd - Admedus discharges first patient following clinical SAVR trial
Results from the study are expected to be available between first quarter 2021 and third quarter 2021

Admedus Ltd (ASX:AHZ) has announced the hospital discharge of its first patient following its clinical surgical aortic valve replacement (SAVR) trial.

On March 27 the company implanted its first ADAPT single-piece 3D aortic valve in a patient with aortic stenosis.

Professor Bart Meuris at the University Hospitals in Leuven, Belgium conducted the cardiac heart valve surgery.

“Pleased” with initial results

Professor Leon Neethling said: “The patient is doing well with normal gradients upon discharge and had an event free recovery.

“I am very pleased with the initial results.

“With our first patient who now has normal haemodynamics and an excellent EOA, I am looking forward to seeing more patients enter into the study in the coming weeks and months.”

Chief executive officer Wayne Paterson said: “We are very pleased with the patient’s recovery so far and will continue to keep the market updated as and when it’s appropriate as study progresses.”

US FDA clearance

Admedus has also announced the US FDA clearance of an indication change to its ADAPT® -treated (bovine pericardium) tissue through the Special 510(k) pathway.

The change extends ADAPT® tissue approval for use in cardiac defects including intracardiac defects, septal defects and valve and annulus repairs.

Paterson said: “This approval marks an important distinction from previous approvals and clears the way for future approvals of ADAPT based material for our aortic valve products.”

Quick facts: Anteris Technologies Ltd

Price: 3.4 AUD

Market: ASX
Market Cap: $20.1 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...



Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

on 6/7/20

2 min read